Drug Approval | May 06, 2022
Zydus receives tentative approval from USFDA for Selexipag tablets
The drug will be manufactured at the group's formulation facility at SEZ, Ahmedabad
The drug will be manufactured at the group's formulation facility at SEZ, Ahmedabad
This agreement is truly remarkable for achieving greater objectives in the projects and addressing larger problems
The research was funded by the National Institutes of Health, the Eversight Center for Vision and Eye Banking Research, and Research to Prevent Blindness
The research was supported by the BGU Coronavirus Challenge and the Israeli Ministry of Health.
Company will expand the existing production site in Wuxi to significantly increase biopharma single-use assemblies and custom design capabilities
The facility is among 12 centres established worldwide, and the first in Asia
The companies expect to complete the submission of the NDA for treatment of MDD in the second half of 2022; associated filing for postpartum depression is anticipated in the first half of 2023
Move brings together AstraZeneca and Alexion colleagues in a purpose-built facility in Kendall Square, Cambridge, MA, a world-leading life sciences hub
The USFDA approval in AS marks the fifth indication for Rinvoq in chronic immune-mediated diseases
Onshore manufacturing facility is expected to be based in Quebec and produce up to 100 million mRNA respiratory vaccine doses annually
Subscribe To Our Newsletter & Stay Updated
